Clinical trial design
CHASIT
DISEASE, DISEASE PROGRESSION, BREDA, PRIMARY TUMOR
The CHASIT trial is a prospective, multicenter, non-randomized single arm phase II clinical trial. The following Dutch hospitals are participating: Erasmus Medical Center in Rotterdam, Amphia hospital in Breda, Radboud University Medical Center in Nijmegen and Jeroen Bosch hospital in Den Bosch. Patients with at least stable disease after treatment with platinum-based chemotherapy (gemcitabine + cisplatin, gemcitabine + carboplatin or (dd)MVAC) are eligible for inclusion and will be treated with avelumab. After avelumab treatment, response evaluation is performed with radiological imaging. In the absence of disease progression, patients are scheduled for surgical excision of the primary tumor and lymph nodes (Fig. 
Flowchart of study design. Abbreviations: CR = complete response, PR = partial response and SD = stable disease